Phase II PETHEMA trial of alternating bortezomib and dexamethasone as induction regimen before autologous stem-cell transplantation in younger patients with multiple myeloma: efficacy and clinical implications of tumor response kinetics.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples